This open-label, randomized phase 2 trial evaluates progression-free survival with chemotherapy plus bevacizumab vs cetuximab among patients with progression of metastatic colorectal cancer (mCRC) after bevacizumab plus chemotherapy.
https://ift.tt/2PkAGq7
Δεν υπάρχουν σχόλια:
Δημοσίευση σχολίου